Time to treatment failure (any reason related to treatment) All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ generalised onset Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to treatment failure due to adverse events All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine leads to lower time to treatment failure due to adverse events All participants… compared with phenytoin (primary outcomes) (high certainty).
1 finding from 1 review
Time to treatment failure due to lack of efficacy All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure due to lack of efficacy All participants… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) All participants Range of compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) Subgroup: focal onset… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: generalised onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Remission · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) All… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review